Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients
出版年份 2015 全文链接
标题
Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients
作者
关键词
-
出版物
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 95, Issue 5, Pages 411-420
出版商
Wiley
发表日期
2015-01-20
DOI
10.1111/ejh.12507
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in -thalassemia major (CORDELIA)
- (2014) D. J. Pennell et al. BLOOD
- IRON CHELATION THERAPY IN THALASSEMIA SYNDROMES
- (2014) Paolo Cianciulli Mediterranean Journal of Hematology and Infectious Diseases
- Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis
- (2013) Mohssen Elalfy et al. PEDIATRIC BLOOD & CANCER
- How I treat transfusional iron overload
- (2012) A. V. Hoffbrand et al. BLOOD
- A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with β-thalassemia major
- (2012) Mohsen S. Elalfy et al. PEDIATRIC BLOOD & CANCER
- Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications
- (2011) Kallistheni Farmaki et al. BLOOD CELLS MOLECULES AND DISEASES
- Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies
- (2011) Ersi Voskaridou et al. BRITISH JOURNAL OF HAEMATOLOGY
- Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia
- (2011) Ali Taher et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Combining two orally active iron chelators for thalassemia
- (2010) Vasilios Berdoukas et al. ANNALS OF HEMATOLOGY
- The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores
- (2010) J. C. Wood et al. BLOOD
- Continued improvement in myocardial T2* over two years of deferasirox therapy in -thalassemia major patients with cardiac iron overload
- (2010) D. J. Pennell et al. HAEMATOLOGICA
- Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone
- (2010) Patricia Evans et al. Translational Research
- Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
- (2009) Ali Taher et al. BRITISH JOURNAL OF HAEMATOLOGY
- Patient-Reported Outcomes of Deferasirox (Exjade®, ICL670) versus Deferoxamine in Sickle Cell Disease Patients with Transfusional Hemosiderosis
- (2008) Elliott Vichinsky et al. ACTA HAEMATOLOGICA
- Inflammation and oxidant-stress in -thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial
- (2008) P. B. Walter et al. HAEMATOLOGICA
- Satisfaction and Adherence in Patients with Iron Overload Receiving Iron Chelation Therapy as Assessed by a Newly Developed Patient Instrument
- (2008) Diana Rofail et al. VALUE IN HEALTH
- Intracellular labile iron
- (2007) William Breuer et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation